Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Enzon Pharmaceuticals ( (ENZN) ) just unveiled an announcement.
On March 18, 2026, Enzon Pharmaceuticals entered into a Tenth Amendment to its Section 382 Rights Agreement, continuing a series of adjustments that have repeatedly modified the plan’s Final Expiration Date since its original adoption in August 2020. The latest amendment pushes the expiration of the rights from noon, New York City time, on March 18, 2026, to noon on March 24, 2026.
This change leaves all other terms of the rights plan unchanged and reflects management’s view that extending the Final Expiration Date to March 24, 2026 is in the best interests of the company and its stockholders, sustaining the protective framework designed around the company’s equity through a slightly longer time horizon.
More about Enzon Pharmaceuticals
Enzon Pharmaceuticals, Inc. is a U.S.-based biopharmaceutical company. It focuses on developing and commercializing therapies in the pharmaceutical sector, with a shareholder base whose interests are affected by equity and tax-related corporate governance measures such as Section 382 rights plans.
Average Trading Volume: 75,175
Technical Sentiment Signal: Sell
Current Market Cap: $4.82M
See more insights into ENZN stock on TipRanks’ Stock Analysis page.